Loading clinical trials...
Loading clinical trials...
To demonstrate that CT-P10 is similar to Rituxan in terms of efficacy as determined by overall response rate at 7 months
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Celltrion
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
NCT06191744 · Follicular Lymphoma (FL)
NCT07545603 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, and more
NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
NCT06337318 · Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Severance Hospital
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions